title: [Clinical trials of ofloxacin in sequential use (intravenous and oral) in patients with serious hospital infection].
abstract: Fifteen patients with severe hospital infections such as postoperative pneumonia or intraabdominal sepsis were treated with ofloxacin in a dose of 400 mg once a day for 7 to 14 days (11 days at the average). The drug was administered intravenously for the first 3-5 days and then orally till the end of the treatment course. The clinical effect was observed in 14 patients (93 per cent) and the positive bacteriological effect was stated in 11 out of 13 patients (85 per cent). Before the treatment 18 microbial cultures were isolated from the patients. 94 per cent of them was susceptible to ofloxacin. The isolates of Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa were the most frequent. The treatment resulted in the eradication of 15 cultures (83 per cent). The adverse reactions were observed in 3 patients but only in 1 of them they were for certain due to the drug use. All the adverse reactions were insignificant or moderate and did not require the treatment discontinuation. The trials showed that ofloxacin was a highly efficient agent useful in the empirical monotherapy of patients with severe hospital infection.
authors.forename: S V
authors.initials: SV
authors.lastname: Iakovlev
authors.forename: L I
authors.initials: LI
authors.lastname: Dvoretskiĭ
authors.forename: T V
authors.initials: TV
authors.lastname: Shakhova
authors.forename: I P
authors.initials: IP
authors.lastname: Kudinkina
authors.forename: P A
authors.initials: PA
authors.lastname: Vorob'ev
authors.forename: N A
authors.initials: NA
authors.lastname: Vlasenko
authors.forename: T S
authors.initials: TS
authors.lastname: Prokhorenko
authors.forename: L V
authors.initials: LV
authors.lastname: Eremina
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003428:Cross Infection / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004925:Escherichia / Q000187:drug effects; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage* / Q000009:adverse effects; D011549:Pseudomonas / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D015242:Ofloxacin